

Information for Connecticut Prescribers of Prescription Drugs Rolvedon® (eflapegrastim-xnst)

(Last updated: 09/2026)

The *Connecticut Public Act 23-171* requires prescription drug manufacturers to disclose in writing to Connecticut prescribing practitioners or pharmacists the list price (i.e., Wholesale Acquisition Cost or “WAC”) of marketed legend drugs when engaging in prescription drug marketing.

The WAC prices listed below represent the Assertio Specialty Pharmaceuticals, LLC (“Assertio”) catalog or list price for the product sold to wholesalers, as reported to applicable pricing compendia at or around the date indicated. WAC does not reflect discounts, rebates and other reductions in price. The price paid by patients may differ from the WAC listed below and may be determined by the individual patient’s insurance coverage.

The prices below do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of all the products listed. For simplicity, only the smallest package sizes available for each product are included. The pricing information listed does not imply safety or efficacy of the product or interchangeability with other products. Please refer to each product’s FDA-approved label and indication for further information.

NDC	MARKETED PRODUCT DESCRIPTION	PKG SIZE	UNIT OF MEASURE	WAC PER PKG
82497-0132-01	ROLVEDON (eflapegrastim-xnst) Injection 13.2mg/0.6mL	1	Single-Dose Prefilled Syringe	\$4,900

Under Connecticut Law, drug manufacturers are also required to provide information on variation efficacy for different racial and ethnic groups if it is available. No research has been performed, and no information is available for any of the marketed products listed.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch (www.fda.gov/medwatch) or call 1-800-FDA-1088.

For complete Prescribing Information of the marketed product, please visit the Assertio website (www.assertiotx.com).